A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Lee NY, O'Meara W, Chan K, Della-Bianca C, Mechalakos JG, Zhung J, et al. Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys 2007;69:459–468.
   PubMed Web of Science ®Google Scholar
• Daly ME, Le QT, Jain AK, Maxim PG, Hsu A, Loo Jr. BW, et al. Intensity-modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx. Head Neck 2011;33:103–111.
   PubMed Web of Science ®Google Scholar
• Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350–7356.
   PubMed Web of Science ®Google Scholar
• Urbano TG, Clark CH, Hansen VN, Adams EJ, Miles EA, Mc Nair H, et al. Intensity modulated radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study. Radiother Oncol 2007;85:58–63.
   PubMed Web of Science ®Google Scholar
• Salama JK, Vokes EE. Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. Semin Oncol 2008;35:251–261.
   PubMed Web of Science ®Google Scholar
• Suh Y, Amelio I, Guerrero Urbano T, Tavassoli M. Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death Dis 2014;5:e1018.
   PubMed Web of Science ®Google Scholar
• Pignon JP, le Maitre A, Maillard E, Bourhis J, GroupM-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4–14.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nature Clin Pract Oncol 2007;4:156–171.
   PubMedGoogle Scholar
• Pignon JP, le Maitre A, Bourhis J, Group M-NC. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007;69:S112–S114.
   PubMed Web of Science ®Google Scholar
• Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006;64:47–56.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567–578.
   PubMed Web of Science ®Google Scholar
• Schrijvers D, Vermorken JB. Taxanes in the treatment of head and neck cancer. Curr Opin Oncol 2005;17:218–224.
   PubMed Web of Science ®Google Scholar
• Specenier P, Vermorken JB. The role of taxanes and targeted therapies in locally advanced head and neck cancer. Curr Opin Oncol 2007;19:195–201.
   PubMed Web of Science ®Google Scholar
• Forastiere AA. Paclitaxel (taxol) for the treatment of head and neck cancer. Semin Oncol 1994;21:49–52.
   PubMed Web of Science ®Google Scholar
• Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;14:1672–1678.
   PubMed Web of Science ®Google Scholar
• Herscher LL, Cook J. Taxanes as radiosensitizers for head and neck cancer. Curr Opin Oncol 1999;11:183–186.
   PubMedGoogle Scholar
• Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636–8645.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695–1704.
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705–1715.
   PubMed Web of Science ®Google Scholar
• Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy(sequentialchemoradiotherapy) versus concurrent chemo-radiotherapy alone in locally advanced head and neck cancer (PARADIGM): Arandomised phase 3 trial. Lancet Oncol 2013;14:257–264.
   PubMed Web of Science ®Google Scholar
• Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther 2007;7:919–943.
   PubMed Web of Science ®Google Scholar
• Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008;19:899–909.
   PubMed Web of Science ®Google Scholar
• Damascelli B, Cantu G, Mattavelli F, Tamplenizza P, Bidoli P, Leo E, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 2001;92:2592–2602.
   PubMed Web of Science ®Google Scholar
• Damascelli B, Patelli GL, Lanocita R, Di Tolla G, Frigerio LF, Marchiano A, et al. A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. Am J Roentgenol 2003;181:253–260.
   PubMed Web of Science ®Google Scholar
• Fury MG, Sherman EJ, Rao SS, Wolden S, Smith-Marrone S, Mueller B, et al. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III–IVB head and neck squamous cell carcinoma (HNSCC). Ann Oncol 2014;25:689–694.
   PubMed Web of Science ®Google Scholar
• Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 2010;28:5294–5300.
   PubMed Web of Science ®Google Scholar
• Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatinwith or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32(27):2940–2950.
   Web of Science ®Google Scholar
• Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 2014;32:2735–2743.
   PubMed Web of Science ®Google Scholar
• Liu YJ, Zhu GP, Guan XY. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncol 2012;48:554–559.
   PubMed Web of Science ®Google Scholar
• Benveniste MF, Korst RJ, Rajan A, Detterbeck FC, Marom EM. A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. J Thorac Oncol 2014;9:S119–S124.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, et al. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24:2390–2396.
   PubMed Web of Science ®Google Scholar
• Satouchi M, Okamoto I, Sakai H, Yamamoto N, Ichinose Y, Ohmatsu H, et al. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2013;81:97–101.
   PubMed Web of Science ®Google Scholar
• Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24–35.
   PubMed Web of Science ®Google Scholar
• Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32:2940–2950.
   PubMed Web of Science ®Google Scholar
• Kies MS, Holsinger FC, Lee JJ, William Jr. WN, Glisson BS, Lin HY, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010;28:8–14.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010;21(Suppl 7):vii252–vii261.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009;2:59–64.
   PubMed Web of Science ®Google Scholar